Results 161 to 170 of about 6,658 (202)

Rucaparib

Reactions Weekly, 2023
openaire   +2 more sources

Rucaparib in the landscape of PARP inhibition in ovarian cancer

Expert Review of Anticancer Therapy, 2019
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target.
Emeline, Colomba, Patricia, Pautier, Fanny, Pommeret, Alexandra, Leary   +3 more
openaire   +2 more sources

Rucaparib

Reactions Weekly, 2022
openaire   +1 more source

Olaparib/rucaparib

Reactions Weekly, 2021
openaire   +2 more sources

Rucaparib

Reactions Weekly, 2021
openaire   +1 more source

Cisplatin/rucaparib

Reactions Weekly, 2021
openaire   +1 more source

Synthesis of Rucaparib

Synfacts, 2022
openaire   +1 more source

Population Exposure-Efficacy and Exposure-Safety Analyses for Rucaparib in Patients With Recurrent Ovarian Carcinoma From Study 10 and ARIEL2

Gynecologic Oncology, 2021
Andrew D Simmons, Ronnie Shapira-Frommer, Michelle Green   +2 more
exaly  

Niraparib/olaparib/rucaparib

Reactions Weekly, 2023
openaire   +1 more source

Rucaparib

Case Medical Research, 2016
openaire   +1 more source